{"entity":{"id":"boston-scientific","kind":"company","name":"Boston Scientific","aka":[],"tldr":"Medical device giant whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer.","summary":"Boston Scientific, based in Marlborough, Massachusetts, and listed as BSX, is the medical device company whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer. TheraSphere has held FDA approval for hepatocellular carcinoma since 2021, was studied in the EPOCH trial in colorectal liver metastases, which was positive for progression-free survival, and is being tested in combination with immunotherapy, and the company also sells drug-eluting embolic beads and other interventional oncology devices. OnCo links it to hepatocellular carcinoma and colorectal cancer and to the radioembolisation and transarterial chemoembolisation technology records. Whether device-based liver-directed therapy keeps its role as systemic options improve is the open question. The technology pages carry the trial detail.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Boston_Scientific","links":[{"label":"Official website","url":"https://www.bostonscientific.com"}],"tags":[],"related":[],"cancers":["hcc","colorectal"],"sections":["radiation","surgery"],"technologies":["radioembolisation-tare","tace"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05063565"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Marlborough, MA","country":"US","companyType":"devices","website":"https://www.bostonscientific.com","ticker":"BSX","investors":[],"funding":[]},"route":"/companies/boston-scientific/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/"}],"technology":[{"id":"cryoablation-systems","kind":"technology","name":"Cryoablation systems","route":"/technologies/cryoablation-systems/"},{"id":"endoscopic-ultrasound-systems","kind":"technology","name":"Endoscopic ultrasound and EBUS systems","route":"/technologies/endoscopic-ultrasound-systems/"},{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/"},{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/"},{"id":"tace","kind":"technology","name":"Transarterial chemoembolisation (TACE)","route":"/technologies/tace/"}],"trial":[{"id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/"}],"roadmap":[{"id":"devices-roadmap","kind":"roadmap","name":"Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants","route":"/roadmaps/devices-roadmap/"}]}}